Make an Inquiry
Accelerating Leishmaniasis Drug Development

Leishmaniasis remains a significant global health challenge, with limited therapeutic options and rising drug resistance underscoring the urgent need for novel interventions. Ace Therapeutics is a preclinical drug development company dedicated exclusively to advancing therapeutics for Leishmaniasis. Leveraging deep domain expertise, Ace Therapeutics offers a comprehensive suite of preclinical solutions spanning target validation, lead optimization, and IND-enabling studies. Our scientific team combines decades of experience in parasitology, medicinal chemistry, and pharmacology with state-of-the-art screening platforms and translational models tailored to the unique biology of Leishmania species. Ace Therapeutics maintains rigorous adherence to international regulatory standards, ensuring the generation of robust, decision-enabling data throughout the drug development continuum. By integrating advanced technologies with specialized scientific insight, Ace Therapeutics empowers partners to de-risk and accelerate the development of effective Leishmaniasis therapeutics. Our unwavering commitment is to drive therapeutic breakthroughs that address this neglected disease and improve patient outcomes worldwide.

What is LeishmaniasisTargets for LeishmaniasisDrug Discovery and Development ServicesWhy Choose Us

What is Leishmaniasis

Leishmaniasis is a vector-borne infectious disease caused by protozoan parasites of the genus Leishmania, transmitted to humans through the bites of infected female phlebotomine sandflies. After transmission, the parasites enter the skin as promastigotes, are engulfed by macrophages, and transform into amastigotes, where they replicate intracellularly and evade immune defenses. The clinical spectrum of leishmaniasis varies based on the Leishmania species and the host’s immune status, with disease severity ranging from localized skin ulcers to life-threatening systemic infection. The disease disproportionately affects populations in tropical and subtropical regions, with socioeconomic and environmental factors contributing to risk. Leishmaniasis presents in three main forms: cutaneous, mucocutaneous, and visceral. Cutaneous leishmaniasis manifests as ulcerative skin lesions, while mucocutaneous disease involves destructive lesions of the mucous membranes, and visceral leishmaniasis (kala-azar) causes systemic symptoms including fever, hepatosplenomegaly, and pancytopenia. Diagnosis relies on clinical assessment, epidemiological context, and laboratory confirmation through microscopy, culture, molecular methods, and serology. Treatment options include liposomal amphotericin B, miltefosine, pentamidine, paromomycin, and pentavalent antimonials such as meglumine antimoniate and sodium stibogluconate. Early diagnosis and appropriate therapy are essential to reduce morbidity, mortality, and long-term complications.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
amphotericin B lipid complex; liposomal amphotericin B; liposome-encapsulated amphotericin B
img-58066-85-6-hexadecylphosphocholinemiltefosine-rec-inn-ban hexadecylphosphocholine; miltefosine (Rec INN; BAN) 58066-85-6 C21 H46 N O4 P 407.568
liposomal amphotericin B
img-100-33-4-free-base140-64-7-pentamidine-isethionate-rec-inn-usan-ban pentamidine isethionate (Rec INN; USAN; BAN) 100-33-4 (free base); 140-64-7 C19 H24 N4 O2 . 2 C2 H6 O4 S 592.683
img-7542-37-2-aminosidineparomomycin-rec-inn-usan-ban aminosidine; paromomycin (Rec INN; USAN; BAN) 7542-37-2 C23 H45 N5 O14 . H2 O4 S 713.707
img-1397-89-3-amphotericin-banamphotericin-b-rec-inn-janamphoter amphotericin (BAN); amphotericin B (Rec INN; JAN); amphotericin B Deoxycholate 1397-89-3 C47 H73 N O17 924.079
img-unknown-meglumine-antimoniateprotostib meglumine antimoniate; protostib C7 H18 N O5 . O3 Sb 365.98
img-16037-91-5-sodium-stibogluconate sodium stibogluconate 16037-91-5 C12 H18 O17 Sb2 . 3 Na . 9 H2 O 908.888

Learn More

Targets for Leishmaniasis

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
Protein Tyrosine Phosphatase Type IVA (nonspecified subtype)
Protein Tyrosine Phosphatase (PTP) (nonspecified subtype)
Interferon (nonspecified subtype)
toll like receptor 7 TLR7
Phosphodiesterase (nonspecified subtype)
chitinase acidic CHIA
acetylcholinesterase (Yt blood group) ACHE
tumor necrosis factor TNF

Therapeutic targeting in leishmaniasis involves both parasite-specific enzymes essential for survival and host immune mediators that influence disease progression. Key parasite targets include Pteridine Reductase 1 (PTR1), which enables Leishmania to bypass antifolate drug inhibition and survive oxidative stress, Ornithine Decarboxylase (ODC), crucial for polyamine biosynthesis and parasite growth, and Ascorbate-dependent Peroxidase, which protects against host-derived oxidative damage. On the host side, Tumor Necrosis Factor (TNF) orchestrates macrophage activation and parasite killing, Toll Like Receptor 7 (TLR7) senses Leishmania RNA to trigger innate immunity, and Heme Oxygenase 1 (HMOX1) modulates inflammation and can create an immunosuppressive environment that aids parasite persistence. These targets offer promising avenues for new therapeutics and biomarkers. PTR1 and ODC are validated drug targets, with inhibitors like antifolates and DFMO showing efficacy in preclinical and limited clinical settings, though resistance and pharmacokinetics remain challenges. Ascorbate-dependent Peroxidase is a novel candidate for drug development. Host targets such as TNF and TLR7 are being explored for immunomodulation, with TLR7 agonists under investigation as vaccine adjuvants. HMOX1 modulation may help shift the balance toward parasite clearance. Collectively, these targets inform drug discovery, therapeutic strategies, and disease monitoring in leishmaniasis.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service for leishmaniasis accelerates drug discovery by providing sensitive, quantitative assays to assess compound potency, cytotoxicity, and mechanism of action. Utilizing chemiluminescent, ELISA, and RNA-based methods, we evaluate key targets such as Heme Oxygenase 1 and Tumor Necrosis Factor in relevant cell models. We deliver critical pharmacological parameters including EC-50, MEC, and MIC to guide candidate selection and optimization. Our robust platforms support early-stage screening and mechanistic studies, enabling clients to advance the most promising anti-leishmanial therapies with confidence and scientific rigor in a streamlined, cost-effective manner.

Heme Oxygenase 1 Tumor Necrosis Factor

Learn More

Why Choose Us

At Ace Therapeutics, we are dedicated to advancing the fight against Leishmaniasis through specialized expertise in research and drug development. Our professional teams bring together years of focused experience in parasitology, medicinal chemistry, and pharmacology, ensuring that every project benefits from deep scientific insight and technical excellence. Utilizing advanced technology platforms, Ace Therapeutics is able to accelerate the discovery and optimization of new therapeutics, offering comprehensive and innovative preclinical solutions tailored to the unique challenges of Leishmaniasis. Our proven track record in preclinical drug development services speaks to our reliability and the trust placed in us by partners worldwide. We adhere to the highest quality standards and maintain strict regulatory compliance throughout every stage of development, safeguarding the integrity and success of your project. Above all, Ace Therapeutics is driven by a genuine commitment to improving global health by delivering effective and safe Leishmaniasis therapeutics. When you choose Ace Therapeutics, you are partnering with a team that values professionalism, reliability, and a shared mission to make a meaningful impact in the field of neglected tropical diseases.

FAQs for Our Services

Q: What are the key preclinical research challenges specific to developing drugs for Leishmaniasis?

A: Preclinical research for Leishmaniasis faces several unique challenges, including the need for robust in vitro and in vivo models that accurately replicate human disease. The parasite’s complex life cycle and genetic diversity across Leishmania species require tailored screening assays and animal models. Additionally, the intracellular nature of the parasite demands drug candidates with excellent cell penetration and bioavailability. Our company addresses these challenges by utilizing validated Leishmania strains, state-of-the-art cell-based assays, and a range of animal models, including hamsters and mice, to ensure translational relevance.

Q: What regulatory considerations should be taken into account during Leishmaniasis drug development?

A: Leishmaniasis is classified as a neglected tropical disease, and regulatory agencies such as the FDA and EMA offer specific guidance and incentives for developing treatments. However, rigorous demonstration of safety and efficacy through GLP-compliant preclinical studies remains essential. Our services include comprehensive toxicology, pharmacokinetic, and efficacy studies in compliance with international regulatory standards, and we assist clients in preparing documentation for orphan drug designation, fast-track status, and other regulatory pathways relevant to neglected diseases.

Q: What are the most important technical aspects to consider in preclinical Leishmaniasis research?

A: Technical considerations include the selection of relevant Leishmania species for screening, development of high-throughput assays for parasite viability, and use of appropriate animal models that mimic human pathology. Drug metabolism and pharmacokinetics (DMPK) studies are also critical, given the need for compounds to reach intracellular parasites within host macrophages. Our team leverages advanced imaging, molecular biology, and bioanalytical platforms to provide comprehensive technical support throughout the preclinical stage.

Q: What is the typical timeline and cost associated with preclinical development of Leishmaniasis drug candidates?

A: The preclinical development phase for Leishmaniasis drug candidates typically spans 12 to 24 months, depending on the complexity of the compound and the extent of required studies. Costs can vary widely, but a comprehensive preclinical package—including efficacy, safety, DMPK, and toxicology studies—generally ranges from $1 million to $3 million USD. Our company provides customized project plans and cost estimates, ensuring transparency and efficient resource allocation for our clients.

Q: What are the critical success factors in the preclinical development of new drugs for Leishmaniasis?

A: Success in preclinical Leishmaniasis drug development relies on several key factors: selection of drug candidates with potent anti-parasitic activity and favorable safety profiles; use of validated, predictive in vitro and in vivo models; early assessment of pharmacokinetic and toxicity parameters; and alignment with regulatory requirements. Our expertise in assay development, disease modeling, and regulatory strategy positions us to help clients maximize the likelihood of advancing candidates to clinical development.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © Ace Therapeutics. All rights reserved.